Clinical Trials in Detroit

Showing 17681-17700 of 19,719 trials

Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors

NCT00485719

The purpose of this study is to determine the safety and tolerability of XL765. XL765 is a new chemical entity that inhibits the kinases PI3K and mTOR. In preclinical studies, inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells, whereas inactivation of mTOR has been shown to inhibit the growth of tumor cells.

Cancer

Sanofi83 participantsStarted Jun 2007

Detroit, Michigan, United States • Omaha, Nebraska, United States • San Antonio, Texas, United States +1 more locations

COMPLETEDPhase 3< 1 mile

Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

NCT00002717

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for ovarian or peritoneal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of paclitaxel plus cisplatin in treating patients who have residual disease after surgery to remove stage III or stage IV ovarian cancer or primary peritoneal cancer.

Ovarian CancerPrimary Peritoneal Cavity Cancer

Gynecologic Oncology Group324 participantsStarted Mar 1996

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +49 more locations

Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors

Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

Find Trials by Condition in Detroit

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer

SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial

Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes

Fecal Biomarker Study for Patients With Ulcerative Colitis

Effects of Interpersonal Psychotherapy on Depression During and After Pregnancy

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain

Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

Quality of Life in Survivors of Gynecologic Cancer

A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.

Stress Management Training in Patients Undergoing Radiation Therapy for Cancer

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function